(C) Wolf G Kroner 2009 - Dr Majid MehtaliStem Cells and Vaccines in Biomanufacturing

November 2009: Dr Majid Mehtali, at the time CSO of Vivalis gives a personal perspective on demand for stem cell application, in particular in biomanufacturing. In the exclusive interview with B2Bioworld he outlines Vivalis’ expansion strategies and answers questions on financing and cash burn.

In May 2013 Vivalis merged with Austrian Intercell and formed Valneva. SE significantly changing the group’s strategy.

* August 10, Dr. Mehtali prematurely passed away after a heart attack at the age of 51.
Addendum by Editor, August 2013

.(C) Wolf G Kroner 2010 Dr. Mahjid Mehtali

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)
6 pages, no adverts

Article free of advertisement - 6 pages
- Includes overview Licences 2002 – 2009 (Licensee, Type of Licence, Scope)

Full Company License enquire here

Back to section

Related Editorial Articles

Leroy Hood: Thinking Further about Stem Cells

Patenting Stem Cells – Behind the Front Stages
The patentability of stem cells is of continuing debate. The article outlines the legal approach to stem cells as it informs solving juridical problems

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

Novartis: Preparing for another Level of Innovation
Mark Fishman, President of the Novartis Institutes for BioMedical Research (NIBR) and Member of the Executive Committee of Novartis, comments stem cell issues including technology acquisitions in the field.

Merck Serono: Clear away complete confusion of terms
Bernhard Kirschbaum, past Head of Global Research and Early Development for Merck Serono on stem cell research

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

The Myriad Way
Peter D Meldrum, at the time CEO of the genetics company about battles on patents, cancer chips, and competitors in commercial academia

Stem Cells – Failings and Deliveries
Hugh Ilyine, longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Bayer AG: New Stakes in Stem Cells
Andreas Busch, Member of the Bayer HealthCare Executive Committee, responsible for Global Drug Discovery

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

GSK: Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Boehringer Ingelheim: We are obliged to more and more move away from animals
Andreas Barner, Chairman of the Board of Managing Directors of Boehringer Ingelheim and Head of Corporate Board Division Pharma Research Corporate, evaluates prospects for stem technologies

Drug Testing with Embryonic Stem Cells
David Hays on standardization issues for therapeutics

Improving the IP System on a global scale: A view from Japan
Sadao Nagaoka, Institute of Innovation Research, and Chief Policy Adviser to the Japanese Government

Is that worth a dollar, or a million dollars?
Ed Torres, Managing Director of Lilly Ventures on the Fund’s input to Eli Lilly’s business development